Cargando…

Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy

OBJECTIVE: This research sought to explore health care providers’ (HCPs) experiences of delivering the first US Food and Drug Administration (FDA) and European Commission (EC) approved peanut oral immunotherapy (peanut OIT; Palforzia). Semi-structured qualitative interviews with HCPs who had initiat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anagnostou, Aikaterini, Lawrence, Claire, Tilles, Stephen A., Laubach, Susan, Donelson, Sarah M., Yassine, Mohamed, Nowak-Wegrzyn, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358114/ https://www.ncbi.nlm.nih.gov/pubmed/35941597 http://dx.doi.org/10.1186/s13104-022-06161-6

Ejemplares similares

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice
por: Portnoy, Jay, et al.
Publicado: (2022)

Peanut immunotherapy
por: Anagnostou, Katherine, et al.
Publicado: (2014)

A Practical, Stepwise Approach to Peanut Oral Immunotherapy in Clinical Practice: Benefits and Risks
por: Anagnostou, Aikaterini
Publicado: (2021)

Peanut allergy burden survey: Factors associated with health‐related quality of life in adolescents
por: McCann, William A., et al.
Publicado: (2023)

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
por: Yu, Shengsheng, et al.
Publicado: (2021)

The Peanut Allergy Burden Study: Impact on the quality of life of patients and caregivers
por: Nowak-Wegrzyn, Anna, et al.
Publicado: (2021)

Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy
por: Blackman, Andrea C., et al.
Publicado: (2019)

Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy
por: Bird, J. Andrew, et al.
Publicado: (2023)

Insights into Microbiome and Metabolic Signatures of Children Undergoing Peanut Oral Immunotherapy
por: Blackman, Andrea C., et al.
Publicado: (2022)

Children and caregiver proxy quality of life from peanut oral immunotherapy trials
por: Galvin, Audrey Dunn, et al.
Publicado: (2022)

Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020)

Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy
por: Anvari, Sara, et al.
Publicado: (2022)

Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
por: Blaiss, Michael S, et al.
Publicado: (2021)

Berberine-containing natural-medicine with boiled peanut-OIT induces sustained peanut-tolerance associated with distinct microbiota signature
por: Srivastava, Kamal, et al.
Publicado: (2023)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

Recent advances in understanding and preventing peanut and tree nut hypersensitivity
por: Kusari, Ayan, et al.
Publicado: (2018)

Allergen-Specific Immunotherapies for Food Allergy
por: Feuille, Elizabeth, et al.
Publicado: (2018)

Oral immunotherapy for peanut allergy: The pro argument
por: Chinthrajah, R. Sharon, et al.
Publicado: (2020)

Peanut Oral Immunotherapy: a Current Perspective
por: Patrawala, Meera, et al.
Publicado: (2020)

Oral immunotherapy for peanut allergy: The con argument
por: Fiocchi, Alessandro, et al.
Publicado: (2020)

Peanut allergy: Beyond the oral immunotherapy plateau
por: Bruton, Kelly, et al.
Publicado: (2021)

Interpreting success or failure of peanut oral immunotherapy
por: Cao, Shijie, et al.
Publicado: (2022)

Transitioning peanut oral immunotherapy to clinical practice
por: Lazizi, S., et al.
Publicado: (2022)

Transitioning from epicutaneous to oral peanut immunotherapy
por: Wong, Lauren, et al.
Publicado: (2023)

The global burden of illness of peanut allergy: A comprehensive literature review
por: Lieberman, Jay A., et al.
Publicado: (2021)

T cell specific and non specific tolerance mechanisms in peanut oil immunotherapy in peanut allergic subjects
por: Singh, Amit, et al.
Publicado: (2011)

A novel peanut allergoid is safe and effective in immunotherapy in a peanut allergy mouse model
por: Smit, J, et al.
Publicado: (2013)

RADIOIMMUNOASSAY OF SERUM ALBUMIN PRODUCED BY HUMAN EMBRYONIC LIVER IN MONOLAYER CULTURE
por: Bissell, D. Montgomery, et al.
Publicado: (1972)

Psychosocial services provided by licensed cardiac rehabilitation programs
por: Bush, Montika, et al.
Publicado: (2023)

Genome of an allotetraploid wild peanut Arachis monticola: a de novo assembly
por: Yin, Dongmei, et al.
Publicado: (2018)

First draft genome of Thecaphora frezii, causal agent of peanut smut disease
por: Arias, Renee S., et al.
Publicado: (2023)

Peanut oral immunotherapy: current trends in clinical trials
por: Reinwald, Simone, et al.
Publicado: (2022)

Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp
por: Leonard, Stephanie A., et al.
Publicado: (2022)

Prescribing for personality disorder: qualitative study of interviews with general and forensic consultant psychiatrists
por: Martean, Lawrence, et al.
Publicado: (2014)

Peanut oral immunotherapy may improve health‐related quality of life among severe peanut allergic adolescents
por: Ödling, Maria, et al.
Publicado: (2023)

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials
por: Blumchen, Katharina, et al.
Publicado: (2023)

Accuracy of pharmaceutical company licensing predictions: projected versus actual licensing dates
por: Doos, Lucy, et al.
Publicado: (2016)

Transcriptomic analyses reveal the expression and regulation of genes associated with resistance to early leaf spot in peanut
por: Gong, Limin, et al.
Publicado: (2020)

Long Non-Coding RNAs Expressed in the Peanut Allergy for Understanding the Pathophysiology of Peanut Allergy Rat Model
por: Liu, Manman, et al.
Publicado: (2022)

Mouse strain differences in response to oral immunotherapy for peanut allergy
por: Wagenaar, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r4ublsrv467bkoep5h29km4sms